Euglycemic DKA in an Adolescent Treated With a Sodium-Glucose Cotransporter-2 Inhibitor

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a class of glucose-lowering medications that were recently approved for pediatric type 2 diabetes (T2D). A serious adverse effect of SGLT2i is euglycemic diabetic ketoacidosis (euDKA), a rare life-threatening metabolic emergency that was recognized after an increase in adult cases noted in postapproval safety surveillance programs. To our knowledge, SGLT2i-assoicated euDKA has not yet been described in youth with T2D since SGLT2i received pediatric approval in 2023. We report on a 17-year-old female patient with T2D on an SGLT2i who developed euDKA. She initially presented with vomiting that improved with antiemetics; however, she had persistent ketosis and developed significant acidosis, prompting diagnosis of euDKA. She was treated with intravenous insulin, dextrose-containing fluids, and electrolyte replacement with resolution of euDKA. This case highlights the challenges of recognizing SGLT2i-asosciated euDKA because of its rarity and the lack of hyperglycemia. As an increasing number of youth are started on SGLT2i, practitioners must be aware of the risk of SGLT2i-associated euDKA to allow for early recognition, adequate treatment, and prevention of serious complications.

Authors

Institutions

Publication Details

Journal
PEDIATRICS
Published
2026-11-18
DOI
https://doi.org/10.1542/peds.2026-077033
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Euglycemic DKA in an Adolescent Treated With a Sodium-Glucose Cotransporter-2 Inhibitor

John T. Walker, Karla F. Leavens, Andrea True Kelly, Patricia Y. Chu
2 links
PEDIATRICS
Diabetes Treatment and Management
article

Euglycemic DKA in an Adolescent Treated With a Sodium-Glucose Cotransporter-2 Inhibitor

John T. Walker, Karla F. Leavens, Andrea True Kelly, Patricia Y. Chu
article en

Abstract

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a class of glucose-lowering medications that were recently approved for pediatric type 2 diabetes (T2D). A serious adverse effect of SGLT2i is euglycemic diabetic ketoacidosis (euDKA), a rare life-threatening metabolic emergency that was recognized after an increase in adult cases noted in postapproval safety surveillance programs. To our knowledge, SGLT2i-assoicated euDKA has not yet been described in youth with T2D since SGLT2i received pediatric approval in 2023. We report on a 17-year-old female patient with T2D on an SGLT2i who developed euDKA. She initially presented with vomiting that improved with antiemetics; however, she had persistent ketosis and developed significant acidosis, prompting diagnosis of euDKA. She was treated with intravenous insulin, dextrose-containing fluids, and electrolyte replacement with resolution of euDKA. This case highlights the challenges of recognizing SGLT2i-asosciated euDKA because of its rarity and the lack of hyperglycemia. As an increasing number of youth are started on SGLT2i, practitioners must be aware of the risk of SGLT2i-associated euDKA to allow for early recognition, adequate treatment, and prevention of serious complications.

PEDIATRICS
Children's Hospital of Philadelphia (US), University of Pennsylvania (US)
Good health and well-being
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon